Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 12

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 12
---
 completed fiscal year.
We may continue
to be a smaller reporting company if either (i)
the market value of our stock held by non-affiliates
is less than $250 million or (ii) our annual revenue
was less than $100 million during the
most recently completed fiscal year and
the market value of our stock held by non-affiliates is less than $700 million as of our most
recently completed second fiscal quarter.
As a smaller reporting company,
we are permitted and intend to rely
on exemptions from certain disclosure
requirements that are applicable to other public companies
that are not smaller reporting companies.

Corporate Information

Our principal offices
are located at 3400 Cottage Way, Suite G2 #32562, Sacramento, CA 95825, and our telephone
number is (424) 222-9301. Our website address is www.lunaibioworks.com; the reference to
such website address does not constitute incorporation
by reference of the information contained on the website
and such information should not be considered part of this prospectus.

<div align='center'>S-6

THE OFFERING</div>

Thefollowing summary contains basic information about this offering. The summary is not intended to be complete. You should read the fu ll text and mo re specific d etails contained elsewhe re in this p rospectus supplement and the accompanying p rospectus. Unless otherwise ind icated, all in formation contained in this p rospectus supplement reflects the R everse Stock Spli t.

| Common                                     
 Stock offered by us:                       |     | Shares                                                                                                                                     
 of Common Stock having an aggregate offering amount of up to $11,702,826.                                                                  |
| Common                                     
 Stock to be outstanding after the offering |     | 32,364,108 shares, assuming the issuance of 8,933,455 shares in this offering                                                              
 at an assumed offering price of $1.31 per share, which was the last reported sale price of our Common Stock on Nasdaq on December 1, 2025. 
 The actual number of shares issued will vary depending on how many shares of our Common Stock we choose to sell and the prices at which    
 such sales occur.                                                                                                                          |
| Plan                                       
 of Distribution                            |     | Sales                                                                                                                                      
 of our Common Stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted          
 by law deemed to be an “at-the-market” offering as